Shu-qiang Q. Yuan

State Key Laboratory Of Oncology In South China, P.R. China
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.

Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 05, 2026

Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial.

Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial.

Journal: Med (New York, N.Y.)

Published: April 02, 2026

The INSPECTOR study: enhanced feasibility for clinical translation of a multi-cancer early detection method based on enzyme-assisted high signal-to-noise ratio sequencing of methylated circulating tumor DNA.

The INSPECTOR study: enhanced feasibility for clinical translation of a multi-cancer early detection method based on enzyme-assisted high signal-to-noise ratio sequencing of methylated circulating tumor DNA.

Journal: Cancer communications (London, England)

Published: July 29, 2025

Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer.

Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer.

Journal: Cancer cell

Published: June 01, 2025

Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

Journal: Cell reports. Medicine

Published: January 14, 2025

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial.

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial.

Journal: Signal transduction and targeted therapy

Published: July 30, 2024

Transcriptional landscape and predictive potential of long noncoding RNAs in peritoneal recurrence of gastric cancer.

Transcriptional landscape and predictive potential of long noncoding RNAs in peritoneal recurrence of gastric cancer.

Journal: Molecular cancer

Published: July 16, 2024

The efficacy of neoadjuvant immunotherapy combined with chemotherapy in elderly patients with gastric cancer: A subgroup analysis of the NEOSUMMIT-01 study.

The efficacy of neoadjuvant immunotherapy combined with chemotherapy in elderly patients with gastric cancer: A subgroup analysis of the NEOSUMMIT-01 study.

Journal: Aging medicine (Milton (N.S.W))

Published: April 17, 2024

Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.

Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.

Journal: Nature medicine

Published: January 08, 2024

Overexpression of COX7A1 Promotes the Resistance of Gastric Cancer to Oxaliplatin and Weakens the Efficacy of Immunotherapy.

Overexpression of COX7A1 Promotes the Resistance of Gastric Cancer to Oxaliplatin and Weakens the Efficacy of Immunotherapy.

Journal: Laboratory investigation; a journal of technical methods and pathology

Published: December 19, 2023

Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure.

Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure.

Journal: ESMO open

Published: December 11, 2023

Construction of a prognostic model for gastric cancer based on immune infiltration and microenvironment, and exploration of MEF2C gene function.

Construction of a prognostic model for gastric cancer based on immune infiltration and microenvironment, and exploration of MEF2C gene function.

Journal: BMC medical genomics

Published: November 10, 2023

Showing 1-12 of 55

Last Updated: 09/26/2026